

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



14th December, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

Sub: Submission of Unaudited Financial Results for the quarter ended on 30th September, 2017

We refer to our letter dated 5th December, 2017 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30th September, 2017.

Please note that the company has adopted IND-AS for the first time from this financial year (2017-18).

We are enclosing herewith copy of the said Unaudited Financial Results.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED


KAMLESH J. LASKARI
MANAGING DIRECTOR



Encl: As above.

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



(Rs. In lakh)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2017

Particulars	Quarter ended on			Half Year ended on (Cumulative)	
	30-09-2017	30-06-2017	30-09-2016	30-09-2017	30-09-2016
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1 Revenue from operations	167.45	289.61	253.71	457.06	543.80
2 Other income	-	0.24	0.27	0.24	0.35
3 Total Income (1+2)	167.45	289.85	253.98	457.30	544.15
4 Expenses					
a. Cost of Materials consumed	109.72	26.76	105.46	136.48	293.54
b. Purchases of stock-in-trade	-	140.30	-	140.30	-
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(11.08)	(6.67)	(0.86)	(17.75)	(55.30)
d. Employee benefits expense	37.82	31.72	37.31	69.54	80.64
e. Finance costs	9.51	15.31	7.45	24.82	23.08
f. Depreciation & amortisation expense	1.46	27.80	1.41	29.26	26.21
g. Other expenses	20.2	53.80	102.45	74.00	174.34
Total Expenses	167.63	289.02	253.22	456.65	542.51
5 Profit / (Loss) before exceptional items and tax (3-4)	(0.18)	0.83	0.76	0.65	1.64
6 Exceptional items	-	-	-	-	-
7 Profit / (Loss) before tax (5-6)	(0.18)	0.83	0.76	0.65	1.64
8 Tax expense:					
Current tax	-	-	-	-	-
Deferred tax	-	-	-	-	-
9 Profit (Loss) for the period from continuing operations (7-8)	(0.18)	0.83	0.76	0.65	1.64
10 Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13 Profit / (Loss) for the period (9+12)	(0.18)	0.83	0.76	0.65	1.64

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



KAMRON

Particulars	Quarter ended on			Half Year ended on (Cumulative)	
	30-09-2017 (Unaudited)	30-06-2017 (Unaudited)	30-09-2016 (Unaudited)	01-04-2017 To 30-09-2017 (Unaudited)	01-04-2016 To 30-09-2016 (Unaudited)
14 Other Comprehensive Income	-	-	-	-	-
<i>Items that will not be reclassified subsequently to profit or loss</i>	-	-	-	-	-
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
<i>Items that will be reclassified subsequently to profit or loss</i>	-	-	-	-	-
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Other Comprehensive Income, net of tax	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14)	(0.18)	0.83	0.76	0.65	1.64
16 Earnings Per Share of Rs.10/- each (for continuing operations)					
- Basic	-	0.01	0.01	0.01	0.03
- Diluted	-	0.01	0.01	0.01	0.03
17 Earnings Per Share of Rs.10/- each (for discontinued operations)					
- Basic	-	-	-	-	-
- Diluted	-	-	-	-	-
18 Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)					
- Basic	-	0.01	0.01	0.01	0.03
- Diluted	-	0.01	0.01	0.01	0.03

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



KAMRON

STATEMENT OF ASSETS AND LIABILITIES

(Rs. In lakh)

Sr.No.	Particulars	As at 30-09-2017
	ASSETS	
1	Non-Current Assets	
	Property, plant and equipment	-
	Capital work-in-progress	-
	Investment property	-
	Goodwill	-
	Other intangible Assets	-
	Intangible Assets under development	79.70
	Biological Assets other than bearer plants	-
	Non-Current Financial Assets:	
	(i) Investments, Non-Current	-
	(ii) Trade receivables, Non-Current	-
	(iii) Loans, Non-Current	-
	Deferred tax Assets (net)	-
	Other Non-Current Assets	1158.78
	Total Non-Current Assets	1238.48
2	Current Assets	
	Inventories	233.81
	Current financial asset:	
	(i) Current investments	-
	(ii) Trade receivables, Current	272.23
	(iii) Cash and cash equivalents	13.75
	(iv) Bank balance other than above	-
	(v) Loans, Current	6.45
	(vi) Other Current financial Assets	13.03
	Current tax Assets (net)	-
	Other Current Assets	337.24
	Total Current Assets	876.51
3	Non-Current Assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	TOTAL ASSETS	2114.99
	EQUITY AND LIABILITIES	
1	Equity	
	Equity share capital	585.00
	Other Equity	119.00
	Total Equity	704.00
2	Liabilities	
	Non-Current Liabilities	
	Non-Current financial Liabilities:	
	(i) Borrowings, Non-Current	400.68
	(ii) Trade payables, Non-Current	107.61
	(iii) Other Non-Current financial Liabilities	24.56
	Provisions, Non-Current	4.59
	Deferred tax Liabilities (net)	-
	Other Non-Current Liabilities	-
	Total Non-Current Liabilities	537.44
	Current Liabilities	
	Current financial Liabilities:	
	(i) Borrowings, Current	738.29
	(ii) Trade payables, Current	-
	(iii) Other Current financial Liabilities	-
	Other Current Liabilities	134.86
	Provisions, Current	0.40
	Current tax Liabilities (Net)	-
	Total Current Liabilities	873.55
3	Liabilities directly associated with Assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total Liabilities	1410.99
	TOTAL EQUITY AND LIABILITIES	2114.99

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



KAMRON

Notes:

1	The Company adopted Indian Accounting Standards (referred to as "Ind AS") with effect from April 1, 2017 and accordingly, the financial results for the quarter ended September 30, 2017 have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
2	The Ind AS financial results and financial information for the quarter ended September 30, 2017 have been compiled by the management after making necessary adjustments to give true and fair view of the results in accordance with Ind AS. This information has not been subjected to limited review.
3	The Company is operating in only one segment i.e. Pharma. Hence segment reporting is not given.
4	The Company does not have any subsidiary / associate.
5	Provision for taxation/deferred taxation, if any, will be made at the year end.
6	Figures, wherever required, are regrouped / rearranged.
7	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 th December, 2017

Reconciliation between financial results as previously reported under Indian GAAP and as per Ind AS for Quarter and Half Year ended on September 30, 2016:

(Rs. In Lakh)

Particulars	Quarter ended on 30-09-2016	Half Year ended on 30-09-2016
Net Profit as reported under Indian GAAP	0.76	1.64
Net Profit as per Ind AS	0.76	1.64
Total Comprehensive Income as per Ind AS	0.76	1.64

Date: 14th December, 2017.

Place : Ahmedabad

For KAMRON LABORATORIES LIMITED



Kamlesh J. Laskari
KAMLESH J. LASKARI
MANAGING DIRECTOR

KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Soia-Santej Road, Tal. Kalol (N. G.),
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



KAMRON

14th December, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

**Sub: Submission of Limited Review Report for Financial Results
for the quarter ended on 30th September, 2017**

We refer to our letter dated 14th December, 2017 enclosing Unaudited Financial Results for the quarter ended on 30th September, 2017.

We are now enclosing herewith Limited Review Report dated 14th December, 2017 for Unaudited Financial Results for the quarter ended on 30th September, 2017.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,
for KAMRON LABORATORIES LIMITED


KAMLESH J. LASKARI
MANAGING DIRECTOR



Encl: As above.

LIMITED REVIEW REPORT

Review Report to the Board of Directors of Kamron Laboratories Ltd.

We have reviewed the accompanying statement of unaudited financial results of Kamron Laboratories Ltd. ("the Company") for the Quarter and Half Year ended 30th September, 2017 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the financial results and other financial information for the Quarter and Half Year ended September 30, 2016 which have been presented solely based on the financial information compiled by the Management.



For RANGWALA & CO
Chartered Accountants
(Firm's Registration No. 115833W)

(Z.E. RANGWALA)
Partner

(Membership No. 031268)

Place of signature: AHMEDABAD
Date: 14th December, 2017